
|Articles|January 10, 2005
Implant provides long-acting treatment for prostate cancer
Luteinizing hormone-releasing hormone (LHRH) agonists are a mainstay in treating locally advanced and metastatic prostate cancer, with the U.S. market for these therapies representing more than $1 billion in annual sales. The market is dominated by four-month and shorter depot injections and implants, such as leupro-lide acetate (Lupron, TAP Pharmaceuticals) for depot suspension and goserelin acetate (Zoladex, Astra Zeneca) implant.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Some Providers Prescribe Unapproved Retatrutide for Weight-Loss at Alarming Rate
2
FDA Approves Bemotrizinol as an OTC Sunscreen Ingredient
3
FDA Approves Lebrikizumab for 8 Week Maintenance of Atopic Dermatitis
4
CDC Will Focus on BA.2.3 COVID-19 Variant for Upcoming Respiratory Season
5





















































